• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCoronavirus

Malaria drug touted as coronavirus treatment by Trump and Elon Musk can be deadly, China finds

By
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Bloomberg
Bloomberg
Down Arrow Button Icon
March 20, 2020, 9:00 AM ET

The drug touted by the U.S. President Donald Trump as a possible line of treatment against the coronavirus comes with severe warnings in China and can kill in dosages as little as two grams.

China, where the deadly pathogen first emerged in December, recommended the decades-old malaria drug chloroquine to treat infected patients in guidelines issued in February after seeing encouraging results in clinical trials. But within days, it cautioned doctors and health officials about the drug’s lethal side effects and rolled back its usage.

This came after local media reported that a Wuhan Institute of Virology study found that the drug can kill an adult just dosed at twice the daily amount recommended for treatment, which is one gram.

As the drug hasn’t been approved by the U.S. Food And Drug Administration to treat the disease known as Covid-19, the Chinese experience may be useful as the American regulator studies the medication which has been endorsed by Trump as well as Tesla Inc. chief executive officer Elon Musk.

Maybe worth considering chloroquine for C19 https://t.co/LEYob7Jofr

— Elon Musk (@elonmusk) March 16, 2020

The pandemic, which has sickened more than 235,000 globally and killed over 9,800 people, has triggered growing anxiety across the U.S. as states say they lack testing kits and medical equipment. California instituted a state-wide lockdown on Thursday to slow the outbreak.

Chloroquine was among the first group of therapies Chinese scientists identified as being effective in curbing the new coronavirus. Clinical trials on about 130 patients demonstrated the drug’s ability to reduce the severity of the illness and speed up virus clearance, according to China’s Ministry of Sciences and Technology.

Chroloquine phosphate was officially recommended on Feb. 19 in the Covid-19 treatment guidelines published by China’s National Health Commission, along with a few other drugs such as AbbVie Inc.’s Kaletra and flu drug arbidol as antiviral treatments for patients. The commission recommended no more than a 10-day course of chloroquine for adult patients at 500mg — half a gram — twice a day.

As hundreds of clinical trials are launched to study potential Covid-19 treatments, stocks of drugmakers and biotechnology companies have racked up big gains on the hope that the industry will see a windfall. But the history of previous viral outbreaks like Ebola and Zika show little success in producing viable treatments. Some potential drugs were developed only after the epidemics already waned through containment measures.

Closely Watched

China’s recommendation to use chloroquine in treatment was quickly followed by a warning.

Two days after the treatment guideline update, health authorities in Hubei province — China’s worst-hit region where the outbreak started and which accounted for majority of its over 80,000 patients — asked hospitals to closely watch for, and immediately report, any adverse side effects of chloroquine phosphate, according to a report in local media outlet The Paper.

The drug is known to have short-term side effects such as nausea, diarrhea and tinnitus while long-term use can irreversibly impair eyesight. It’s forbidden for pregnant women as it can cause congenital defects in babies.

China Health Commission revised the dosage in a Feb. 29 notice tightening chloroquine use. The drug cannot be given to pregnant women, those with heart disease, terminal liver and renal disease, retina and hearing loss and patients on antibiotics such as azithromycin and steroid.

It can now be given only to patients between 18 to 65 years of age for a seven-day treatment course. Patients weighing over 50 kilograms (110 pounds) can take 500mg twice a day — the usual dose — while those weighing less will be administered the drug just once a day after two days of use, according to the latest guidelines.

A woman in Wuhan proved how lethal chloroquine can be when it’s taken beyond the recommended dose. On Feb. 25, Shanghai-based The Paper reported that she took 1.8 grams of the drug she ordered online after suspecting she had the coronavirus. She did not, but the drug caused her to develop malignant cardiac arrhythmic, which can cause sudden death, and she was admitted to the intensive care unit.

More coronavirus coverage from Fortune:

—This famed economist doesn’t think we’re headed for another Great Recession
—South Korea has the most comprehensive coronavirus data. What it’s taught us so far
—10 questions about the 2020 election during the coronavirus pandemic, answered
—6 steps to sustainably flatten the coronavirus curve
—How hackers are exploiting the coronavirus—and how to protect yourself
—Hong Kong launches surveillance operation to track suspected coronavirus patients
—Listen to Leadership Next, a Fortune podcast examining the evolving role of CEO
—WATCH: The race is on to create a coronavirus antiviral drug and vaccine

Subscribe to Fortune’s Outbreak newsletter for a daily roundup of stories on the coronavirus outbreak and its impact on global business.

About the Author
By Bloomberg
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

hybrid
Future of Workhybrid
‘Hybrid creep’ is the latest trick bosses are using to get workers back in the office
By Nick LichtenbergJanuary 13, 2026
9 hours ago
Successthe future of work
Robot surgeons in 3 years, longer lifespans, and no need for retirement savings: Elon Musk shares 4 bold predictions for the future of work
By Orianna Rosa RoyleJanuary 13, 2026
10 hours ago
Healthexercise
5 daily tasks that can double as exercise
By Molly Liebergall and Morning BrewJanuary 12, 2026
1 day ago
A smartphone displaying the app icon for Anthropic AI chatbot Claude displayed against a backdrop that also says "Claude."
AIAnthropic
Anthropic unveils Claude for Healthcare, expands life science features, and partners with HealthEx to let users connect medical records
By Jeremy KahnJanuary 11, 2026
2 days ago
Elon Musk, wearing a suit, puts his knuckles together and looks upward.
TechElon Musk
Elon Musk asked people to upload their medical data to X so his AI company could learn to interpret MRIs and CT scans
By Sasha RogelbergJanuary 11, 2026
2 days ago
SuccessLongevity
CEO coach to the Fortune 500: The most powerful way to tackle 2026 is assuming you’ll live till 130
By Bill HoogterpJanuary 10, 2026
4 days ago

Most Popular

placeholder alt text
Economy
Treasury spent $276 billion in interest on the national debt in the final three months of 2025, says the CBO—up $30 billion from a year prior
By Eleanor PringleJanuary 12, 2026
2 days ago
placeholder alt text
Newsletters
The oil CEO who stood up to Trump is a follower of the disciplined 'Exxon way' and has a history of blunt statements
By Jordan BlumJanuary 13, 2026
15 hours ago
placeholder alt text
Tech
Elon Musk asked people to upload their medical data to X so his AI company could learn to interpret MRIs and CT scans
By Sasha RogelbergJanuary 11, 2026
2 days ago
placeholder alt text
Economy
The longer the Supreme Court delays its tariff decision, the better it is for President Trump
By Jim EdwardsJanuary 13, 2026
14 hours ago
placeholder alt text
Success
An exec at $62 billion giant Colgate says Gen Z workers, despite getting flak for being woke and lazy, are actually ‘pushing us to get better’
By Emma BurleighJanuary 10, 2026
4 days ago
placeholder alt text
Economy
‘Sell America’: Investors dump U.S. assets in fear of the end of Fed independence
By Jim EdwardsJanuary 12, 2026
2 days ago

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.